Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (378)	11/20/1999 8:49:00 PM
From: Bob L	Respond to of 666

Dosimetry is an important consideration, but I'm not sure I see a weight of evidence in these abstracts that favors Bexxar. The jury is still out on whether dosimetry will be a significant problem for Idec in clinical application. As to the theory that yttrium collecting in bone will cause more marrow problems than with iodine, I sure like to see more on that. Not saying its a bad theory, just haven't seen anything that really ties this idea to zevalin in practice. I'm just being a bit of the devil's advocate here. As you know, I hope for nothing but the best for Bexxar.